Ddavp

Polyuria, Nocturia, Polydipsia + 14 more
Treatment
17 Active Studies for Ddavp

What is Ddavp

DesmopressinThe Generic name of this drug
Treatment SummaryDesmopressin (dDAVP) is a synthetic hormone used to treat conditions that involve excessive urination, such as nocturia, diabetes insipidus, and primary nocturnal enuresis. It also helps treat mild classical hemophilia and von Willebrand's disease for minor surgeries. Desmopressin is an improved version of the naturally occurring hormone vasopressin, and it was approved by the FDA in 2018. It is available in a variety of forms, including intranasal solution, intravenous solution, oral tablets, and sublingual tablets.
Ddavpis the brand name
image of different drug pills on a surface
Ddavp Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ddavp
Desmopressin
1978
101

Effectiveness

How Ddavp Affects PatientsDesmopressin is a drug that helps the body retain water by mimicking the action of a natural hormone, anti-diuretic hormone (ADH). It is more effective than ADH at increasing the levels of factor VIII in patients with hemophilia and von Willebrand's disease. Desmopressin does not increase blood pressure like some other drugs, and is much less effective when taken as a nasal spray than as an injection.
How Ddavp works in the bodyWhen desmopressin binds to V2 receptors in the kidneys, it causes cells in the distal tubule and collecting ducts to insert water channels, called aquaporins, into the membrane. This increases the permeability of the membrane to water.

When to interrupt dosage

The measure of Ddavp is contingent upon the diagnosed malady, including Minor Surgical Procedures, Pituitary Gland and Surgery, Hemophilia A. The portion of dosage is contingent upon the approach of delivery featured in the table beneath.
Condition
Dosage
Administration
Nocturia
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Polydipsia
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
von Willebrand Disease
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Hemophilia A
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Pituitary Diseases
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Uremia
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Hemorrhage
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
von Willebrand Disease
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Hemorrhage
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Hemophilia A
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Diabetes Insipidus, Neurogenic
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Pituitary Surgery
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Polyuria
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Nocturnal Enuresis
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Minor Surgical Procedures
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Polyuria
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Hemophilia A
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Spray, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Warnings

Ddavp Contraindications
Condition
Risk Level
Notes
Hyponatremia
Do Not Combine
Renal Insufficiency
Do Not Combine
Hyponatremia
Do Not Combine
There are 20 known major drug interactions with Ddavp.
Common Ddavp Drug Interactions
Drug Name
Risk Level
Description
1-benzylimidazole
Minor
The risk or severity of hypertension can be increased when Desmopressin is combined with 1-benzylimidazole.
2,5-Dimethoxy-4-ethylamphetamine
Minor
The risk or severity of hypertension can be increased when Desmopressin is combined with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamine
Minor
The risk or severity of hypertension can be increased when Desmopressin is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
Minor
The risk or severity of hypertension can be increased when Desmopressin is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-Methoxyamphetamine
Minor
The risk or severity of hypertension can be increased when Desmopressin is combined with 4-Methoxyamphetamine.
Ddavp Toxicity & Overdose RiskTaking too much desmopressin can cause a low level of sodium, or hyponatremia. Symptoms of this include seizures, disorientation, confusion, drowsiness, or a continuing headache, as well as an irregular heartbeat and swelling. If you think you have taken too much desmopressin, lower the dose or stop taking it. Have your sodium levels checked by a doctor, and start any necessary treatment.
image of a doctor in a lab doing drug, clinical research

Ddavp Novel Uses: Which Conditions Have a Clinical Trial Featuring Ddavp?

There are presently 30 active studies assessing the potential of Ddavp to mitigate Polyuria, Hemophilia A and Hemophilia.
Condition
Clinical Trials
Trial Phases
Pituitary Diseases
0 Actively Recruiting
Hemorrhage
0 Actively Recruiting
Pituitary Surgery
0 Actively Recruiting
von Willebrand Disease
5 Actively Recruiting
Phase 3, Phase 1, Phase 2
Hemophilia A
3 Actively Recruiting
Phase 3, Phase 1
Uremia
0 Actively Recruiting
Nocturia
3 Actively Recruiting
Phase 4, Not Applicable
Polyuria
0 Actively Recruiting
Minor Surgical Procedures
0 Actively Recruiting
von Willebrand Disease
0 Actively Recruiting
Polydipsia
0 Actively Recruiting
Diabetes Insipidus, Neurogenic
2 Actively Recruiting
Phase 1, Early Phase 1
Hemophilia A
0 Actively Recruiting
Polyuria
0 Actively Recruiting
Hemorrhage
0 Actively Recruiting
Hemophilia A
0 Actively Recruiting
Nocturnal Enuresis
4 Actively Recruiting
Phase 3, Not Applicable

Ddavp Reviews: What are patients saying about Ddavp?

5Patient Review
10/14/2010
Ddavp for Diabetes Insipidus
We've had great success with this medication for my two kids. My son took it for about a year with no problems whatsoever, and now my daughter is taking it too. So far so good!
5Patient Review
11/30/2010
Ddavp for Bedwetting
This treatment has been essential for me. I have a condition called panhypopituitarism, which means that my pituitary gland was removed. This medication helps me to control my urine flow and has literally saved my life.
5Patient Review
4/6/2014
Ddavp for Diabetes Insipidus
Unfortunately, we didn't see any results from using this treatment. We followed the instructions to a tee and even doubled up when advised by our doctor, but saw no improvement. This was very frustrating and a waste of money.
5Patient Review
9/7/2010
Ddavp for Diabetes Insipidus
Unfortunately, this treatment didn't work for my son at all.
5Patient Review
1/14/2013
Ddavp for Diabetes Insipidus
After being diagnosed with DI, I tried the nasal spray for a year. But I wasn't convinced that it always worked, so I switched to tablets. After several changes in dosage, I feel like we've finally got it right. This medicine has honestly changed my life--I felt like I had gotten my life back. However, now I am wondering if it is changing my mood because I am feeling depressed recently.
4.7Patient Review
3/2/2016
Ddavp for Bedwetting
Despite trying a number of things, my son was still wetting the bed every single night. Finally, we tried this medication and it has not worked at all. We're going to try doubling the dosage tonight and see if that makes any difference. Will update soon.
4Patient Review
9/28/2012
Ddavp for Diabetes Insipidus
My daughter has been using this treatment for more than two years with great success. She uses the nasal spray, one squirt each night. However, I have noticed that she has gained weight in the last two years and I'm not sure if it's from the medicine or not. Are there any other alternatives to bedwetting than desmopressin?
3.7Patient Review
8/1/2010
Ddavp for Diabetes Insipidus
My 9-year-old daughter tried this medication for bedwetting, but it didn't work at all. Additionally, she had a severe allergic reaction after just three days of use (rash).
2.3Patient Review
7/23/2015
Ddavp for Bedwetting
Though it's not as effective as the nasal spray, this pill is more even in its effects and gentle on my nose. The only downside is that I have to remember to take it three times a day.
2.3Patient Review
5/14/2010
Ddavp for Bedwetting
2Patient Review
6/20/2010
Ddavp for Bedwetting
1.7Patient Review
4/5/2011
Ddavp for Bedwetting
We just started this medication last night, and my daughter is already seeing some results. However, I'm concerned about the potential side effects of this drug, specifically with regards to mood changes or obsessive behaviors in children. Has anyone else experienced this?
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ddavp

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is DDAVP given for?

"DDAVP is used to help stop bleeding in patients with von Willebrand's disease or mild hemophilia A by causing the release of von Willebrand's antigen from the platelets and the cells that line the blood vessels where it is stored."

Answered by AI

What is the difference between desmopressin and DDAVP?

"This medication is used to treat diabetes insipidus, bedwetting, hemophilia A, von Willebrand disease, and high blood urea levels."

Answered by AI

What is DDAVP in diabetes insipidus?

"Desmopressin is a synthetic form of vasopressin that helps decrease the amount of urine made by working on the kidneys."

Answered by AI

How does DDAVP work for bleeding?

"DDAVP works by increasing the levels of factor VIII and von Willebrand factor in the blood, which typically last for 12 to 24 hours. This effect is usually enough to control minor bleeding and to prevent bleeding during minor operations, such as dentistry."

Answered by AI

Clinical Trials for Ddavp

Have you considered Ddavp clinical trials? We made a collection of clinical trials featuring Ddavp, we think they might fit your search criteria.Go to Trials
Image of Massachusetts General Hospital in Boston, United States.

Norethindrone Acetate-Ethinyl Estradiol for Oxytocin Deficiency

18 - 65
All Sexes
Boston, MA
This is an open-label, pilot study, to characterize oxytocin response to a single dose of oral Estrogen-progestin in patients with arginine-vasopressin deficiency compared to healthy controls. The association between oxytocin levels and measures of psychopathology (i.e., anxiety and depression) and quality of life across groups will be examined. We hypothesize that: 1. Salivary and blood oxytocin response to Estrogen-progestin will be lower in arginine-vasopressin deficiency compared to healthy control. 2. Lower salivary and blood oxytocin levels will be associated with more severe symptoms of anxiety, depression, and social emotional difficulties as well as lower quality of life.
Phase < 1
Recruiting
Massachusetts General HospitalElizabeth A Lawson, MD
Image of Albany Medical College in Albany, United States.

TENS for Bedwetting

5 - 17
All Sexes
Albany, NY
Children referred to pediatric urology clinic for primary nocturnal enuresis will be screened for enrollment. Patients who fail will next be offered therapy with a bedwetting alarm device or a TENS unit as an alternative, and those who chose TENS therapy will be included in the study.The patients will be randomized into two groups of 35 patients each.Group 1 will be the high pulse width set at 260us. Group 2 will be the low pulse width set at 50us. The patients will be provided with a TENS unit and electrode pads and caretakers instructed on how to use the apparatus. The child's TENS unit will be set at a pulse width determined by randomization, frequency of 10Hz, and an intensity to be determined in the office based upon when the child feels sensitive to the TENS unit. The child will be randomized and will place the electrodes along the posterior tibial nerve on the medial ankle each night before bed time for 30 minutes for a total of 30 days. Diaries including nighttime incontinence episodes and a "wet sheet" scale (dry, damp, wet, soaked) will be recorded, along with any adverse reactions to the TENS unit. Patients will be followed up after one month of TENS with evaluation including the Bowel \& Bladder Questionnaire (BBQ), a validated tool for measuring symptoms in children with voiding dysfunction \[6\]; this questionnaire will be filled out prior to starting TENS treatment in order to compare the effect of treatment. The data will be collected at different time points (baseline and after 1 month of treatment) for each group by itself and the groups compared against each other using statistical analysis.
Recruiting
Has No Placebo
Albany Medical CollegeAdam Howe, MD
Have you considered Ddavp clinical trials? We made a collection of clinical trials featuring Ddavp, we think they might fit your search criteria.Go to Trials
Image of Massachusetts General Hospital, Neuroendocrine Unit in Boston, United States.

Intranasal Oxytocin for Central Diabetes Insipidus

18 - 60
All Sexes
Boston, MA
This is a randomized, double-blind, placebo-controlled crossover pilot study of single-dose intranasal oxytocin (6 IU and 24 IU) vs. placebo in adult men and women (aged 18 years and above) with arginine-vasopressin deficiency to evaluate the effect of oxytocin on anxiety, depression, and socioemotional functioning (Part A), with an optional randomized, double-blind, placebo-controlled 2-week repeated dose substudy of intranasal oxytocin 6 IU or placebo (Part B). Following a screening visit to determine eligibility, participants will return for three main study visits in Part A. During the main study visits, study participants will receive either oxytocin or placebo, followed by assessments of emotional behavior. In Part A, thirty participants will be equally randomized to one of six possible groups: 1. 6 IU oxytocin - 24 IU oxytocin - placebo 2. 6 IU oxytocin - placebo - 24 IU oxytocin 3. 24 IU oxytocin - 6 IU oxytocin - placebo 4. 24 IU oxytocin - placebo - 6 IU oxytocin 5. placebo - 6 IU oxytocin - 24 IU oxytocin 6. placebo - 24 IU oxytocin - 6 IU oxytocin Following completion of the Part A crossover portion of the study, in Part B participants may also choose to continue participation in an optional, randomized, double-blind, placebo-controlled substudy of intranasal oxytocin 6 IU or placebo three times a day for two weeks, followed by assessments of emotional behavior.
Phase 1
Recruiting
Massachusetts General Hospital, Neuroendocrine UnitElizabeth A Lawson, MD, MMScTonix Pharmaceuticals, Inc.
Have you considered Ddavp clinical trials? We made a collection of clinical trials featuring Ddavp, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security